A5059855685- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal cell carcinoma treatment
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Advanced Breast Cancer Therapies
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Palliative Care and End-of-Life Issues
- Intraperitoneal and Appendiceal Malignancies
- Renal and related cancers
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Health Systems, Economic Evaluations, Quality of Life
- Pancreatic and Hepatic Oncology Research
- Management of metastatic bone disease
- Glycosylation and Glycoproteins Research
- Colorectal Cancer Screening and Detection
Praxis für Hämatologie und Onkologie
2007-2025
University of Hildesheim
2004-2024
Praxis
2014
Charité - Universitätsmedizin Berlin
2004-2007
Mayo Clinic in Florida
2007
Klinikum Leverkusen
2005-2007
Johnson & Johnson (United Kingdom)
2007
Charing Cross Hospital
2007
Johannes Gutenberg University Mainz
2007
Universitätsklinikum Tübingen
2005
To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid (FUFOX) as first-line therapy for patients metastatic colorectal cancer (MCRC).A total 474 MCRC received either CAPOX (capecitabine 1,000 mg/m2 bid, days 1 to 14 70 and 8, repeated every 22 days) ) or FUFOX (oxaliplatin 50 followed by leucovorin 500 FU 2,000 a 22-hour infusion 1, 15, 22, 36 days). The primary end point was progression-free survival (PFS). Secondary points were response...
Understanding how to sequence targeted therapies for metastatic renal cell carcinoma (mRCC) is important maximisation of clinical benefit. To prospectively evaluate sequential use the multikinase inhibitors sorafenib followed by sunitinib (So-Su) versus (Su-So) in patients with mRCC. The multicentre, randomised, open-label, phase 3 SWITCH study assessed So-Su Su-So mRCC without prior systemic therapy, and stratified Memorial Sloan Kettering Cancer Center risk score (favourable or...
BackgroundThe present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens disease progression in multiple myeloma (MM) patients.Patients MethodsAdult patients initiating any new MM therapy from October 2010 2012 were eligible. A multistage patient/site recruitment model was applied minimize the selection bias; enrollment stratified by country, region, practice type. The patient medical features, history, remission status recorded...
393 Background: The sequential use of SO and SU has been investigated retrospectively in patients with mRCC. We report here results from the first randomized study to prospectively compare SO/SU versus SU/SO. Methods: Pts mRCC unsuitable for cytokines without prior systemic therapy, ECOG PS 0/1, MSKCC score low or intermediate, ≥1 measurable lesion were receive open-label (arm A) SU/SO B) standard dosage. Primary endpoint: total PFS (T-PFS) randomization event during 2 nd line therapy....
4030 Background: The combination of Bev with 5-FU/FA and irinotecan or oxaliplatin is highly active in ACRC. A recent phase III trial demonstrated that infusional 5-FU capecitabine (cape) have comparable efficacy when combined (Cassidy et al. 2007). In contrast, data are heterogeneous for cape/irinotecan combinations. This randomized II compared safety either CapOx CapIri as first line therapy Methods: Prerequisites were: untreated ACRC, ECOG PS≤2, measurable lesion(s), adequate hematologic...
An increasing proportion of patients are exposed to anthracyclines and/or taxanes in the adjuvant or neoadjuvant setting. Re-exposure metastatic stage is limited by drug resistance, thus evaluation non-cross-resistant regimens mandatory. Anthracycline-pretreated were randomly assigned three gemcitabine-based regimens. Chemotherapy consisted gemcitabine 1.000 mg m−2 plus vinorelbin 25 on days 1+8 (GemVin), cisplatin 30 (GemCis), capecitabine 650 b.i.d. orally 1–14 (GemCap), q3w. The primary...
Introduction: So far, treatment of asymptomatic, early stage CLL patients has not been proven beneficial. Ibrutinib is a BTK inhibitor with impressive clinical efficacy in advanced or relapsed CLL. Therefore we wished to evaluate whether ibrutinib prolongs event-free survival (EFS) increased risk progression. Methods: Asymptomatic Binet A were stratified according recently developed score (Pflug et al., Blood 2014). Patients intermediate, high and very randomized 1:1 receive 420 mg per day...
3507 Background: In a previous phase III study the FUFOX regimen has shown superior response rates to bolus 5-FU/FA (Mayo Clinic protocol) in patients with MCRC (Grothey, ASCO 2002). The combination of capecitabine (CAP) and oxaliplatin (OX) demonstrated good efficacy safety results recent II studies. August 2002 we initiated trial compare CAPOX as first line therapy MCRC. Here, present analysis. Patients methods: From 2004 476 (m:f = 299:177; median age 65 (range 32–86)) have been...
3575
Purpose: Several randomized trials investigating the preferable first-line combination chemotherapy regimen for metastatic colorectal cancer have shown inconsistent findings. Because a substantial number of patients are still being treated with "chemo-only" therapies without targeted agents, we compared overall survival (OS) in routine practice oxaliplatin–fluoropyrimidine and irinotecan–fluoropyrimidine. Patients methods: Using database Tumor Registry Colorectal Cancer, identified 605 who...
4034 Background: Bevacizumab (Bev) combined with 5-FU/FA and both, irinotecan or oxaliplatin are standard regimens for mCRC. Recently, a phase III trial has demonstrated that infusional 5-FU can be substituted by capecitabine (cape) when Bev whereas conflicting data available feasibility efficacy of cape/irinotecan combinations. This randomized II was to compare safety either CapOx CapIri in untreated Methods: Eligibility criteria: mCRC pts, ECOG PS <= 2, measurable lesion(s), adequate...
4567 Background: Results of the sequential randomized phase III SWITCH study comparing SO/SU and SU/SO have been reported previously (ASCO GU 2014, abstract 393) showing no significant difference in primary endpoint total PFS (T-PFS, Hazard Ratio [HR] 1.01) nor secondary endpoints overall survival (OS, HR 1.0) 1st-line (HR 1.19). We here report results subgroup analyses per T-PFS, OS, PFS. Methods: Pts with mRCC unsuitable for cytokines without prior systemic therapy, ECOG PS 0/1, MSKCC...
Levels of experience and competence in palliative medicine vary considerably among physicians. The aim the study was to collect information from specially interested general practitioners on education, pivotal lectures regarding delivery care.92 (41 women 22 men) attending a basic course were asked fill standardized questionnaire relating their knowledge medicine. 63 responded (68%), 54 private practice, nine worked hospital. same number urban rural health care facilities.The majority those...
4539 Background: Several retrospective studies have investigated the sequential use of SO and SU. Some smaller trials support followed by SU forming rationale for this study. Methods: Pts with metastatic RCC unsuitable cytokines without prior systemic therapy, ECOG PS 0/1, MSKCC score low or intermediate, ≥1 measurable lesion (CT/MRI every 12 weeks) were randomized to SO->SU SU->SO in standard dosage (primary endpoint total PFS from randomization event during 2 nd line therapy)....
Introduction: We present the final analysis of phase 3, double-blind, placebo-controlled CLL12 trial evaluating ibrutinib in patients with early stage CLL at increased risk progression defined by a comprehensive score (NCT02863718). Methods: randomly assigned asymptomatic, treatment-naïve Binet A 1:1 ratio to receive (n = 182) or placebo 181) dose 420 mg daily. Patients low were allocated watch and wait group (W&W; n 152). The evaluated event-free survival (EFS; as time symptomatic...